Maria Eloisi Caldas Lopes
Core Facility Leader
Biography
Dr. Caldas-Lopes is originally from Brazil and earned her PhD in Biological Sciences from the University of Buenos Aires, Argentina. Her doctoral work focused on the mechanisms regulating multidrug resistance and apoptosis in leukaemia, for which she received the PhD Annual Award for the best thesis from the University of Pharmacy and Biochemistry. She graduated summa cum laude with outstanding merit from the Immunology Graduate School Program.
Following her doctoral studies, she pursued postdoctoral training at the MD Anderson Cancer Center in Texas and the Albert Einstein College of Medicine in New York, further strengthening her expertise in cellular and molecular oncology research. She went on to hold research associate positions at Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine in New York City. Her research has consistently focused on haematological malignancies, bridging fundamental discoveries with clinical applications.
Dr. Caldas-Lopes has contributed to the preclinical development of novel therapeutic agents, including the Heat Shock Protein 90 (HSP90) inhibitor PU-H71, which has since progressed to FDA-approved clinical trials for multiple tumour types.
Her scientific contributions include peer-reviewed publications in leading journals such as Nature Medicine, Proceedings of the National Academy of Sciences USA (PNAS), Cancer Research, Leukemia & Lymphoma, Leukemia Research and others Link Publications. She has also received multiple awards from organizations including the American Society of Hematology (ASH), the American Association for Cancer Research (AACR), and the Florencio Fiorini Foundation.